The first drug is sailing through trials exceeding expectations. Initially aiming to slow progression of the disease it is reversing the disease process. I think you are trying to show I’m us in your picture the retina in a dish. PYC adds an extra step to their trials to ensure a high likelihood of success. They take human tissue with the disease grow it outside the human and apply their drug. Once they get to trial they know how a drug is likely to behave in human tissue, they have tested it in primates. In addition RNA therapies have a much higher probability of success than usual drugs. By the time they reach human trials the orobability of success is exceedingly high.
in those retina in dish pictures you can see some cells recovering. Not surprising that the drug has so far exceeded expectations. For the ADPKD (the blockbuster 10 billion). They took tissue from people who had renal transplants for the disease. Again they showed reversal of the disease process.
The low toxicity is not related to the site of injection. It is due to the Cell penetrating peptide. Peptide molecules patented by PYC that can carry RNA modifying drugs across the cell membrane. (Potentially having value in their own right). They allow far lower doses of the drug to be administered and therefore reduce the possibility of toxicity independent of the organ targeted.
Eagle
PYC Price at posting:
19.5¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)